By SaiyanMed Research Team · Updated 5 November 2026 · For in-vitro research use only
RESEARCH USE ONLY — PROFESSIONAL LABORATORY USE. This article is for qualified laboratory personnel carrying out in-vitro assays or institutionally approved laboratory animal studies. It is not a home-use, personal-use, human-use, or veterinary-use guide. The information below must not be used as an administration, formulation, reconstitution, or dosing plan. EloraTZP is an investigational combination (eloralintide + tirzepatide). Its safety and efficacy have not been approved for marketing by the FDA or other regulators as this combination product. Clinical trial results are summarized here as published research data, not as medical advice. SaiyanMed does not list an EloraTZP combination SKU on this page. Component educational and RUO references (e.g., eloralintide) are linked separately.
Quick answer
EloraTZP is Eli Lilly and Company’s investigational combination of eloralintide (a selective long-acting amylin receptor agonist; development code LY3841136) and tirzepatide (a dual GIP / GLP-1 receptor agonist; the active ingredient in approved tirzepatide products). Sponsor framing describes EloraTZP as engaging three complementary nutrient-stimulated hormone pathways — GIP, GLP-1, and amylin — with minimal activity at the calcitonin receptor [Lilly IR 2026-09-30].
At the 62nd EASD Annual Meeting in Milan (results announced 30 September 2026), Lilly reported a 48-week Phase 2b study (NCT06603571) in 367 adults with obesity or overweight and type 2 diabetes. In that study, eloralintide and tirzepatide were given as separate subcutaneous injections; Lilly stated plans to advance an EloraTZP co-formulation into Phase 3 by the end of 2026 / in Q4 2026 [Lilly IR 2026-09-30; NCT06603571].
Public Phase 3 registry records for the co-formulation use development code LY900043 under the AMPLIFY program acronym — for example AMPLIFY-1 (NCT07881432) and AMPLIFY-2 (NCT07881458). That is not the same development lane as mono-eloralintide ENLIGHTEN Phase 3 trials (e.g., ENLIGHTEN-1 NCT07321886).
EloraTZP is not: a single unimolecular peptide (contrast zenagamtide / amycretin); mono-eloralintide; tirzepatide alone; Novo’s CagriSema (cagrilintide + semaglutide); or retatrutide (GIP/GLP-1/glucagon triple agonist).
Components: eloralintide + tirzepatide
Eloralintide (amylin pathway)
Eloralintide is Lilly’s investigational once-weekly selective amylin receptor agonist, previously known as LY3841136. Sponsor materials describe potential effects on calorie intake via satiety biology and note minimal calcitonin-receptor activity as part of the selectivity story when discussing EloraTZP [Lilly IR 2026-09-30]. Mono-eloralintide is already in Phase 3 ENLIGHTEN obesity/related programs and has a separate Phase 2b obesity history (NCT06230523 cited in the same Lilly release) [Lilly IR 2026-09-30].
Deep mono reading on SaiyanMed: What Is Eloralintide? · Eloralintide RUO product (component reference material — not an EloraTZP co-formulation vial) · Eloralintide vs Cagrilintide · Eloralintide vs Retatrutide.
Tirzepatide (GIP + GLP-1 pathway)
Tirzepatide is a dual GIP and GLP-1 receptor agonist. Approved tirzepatide products exist for certain labeled indications; EloraTZP as a combination / co-formulation candidate remains investigational [Lilly IR 2026-09-30]. In NCT06603571 the registry lists tirzepatide as LY3298176 alongside LY3841136 [NCT06603571].
How the combination is labeled in development
| Label | Meaning in public records |
|---|---|
| EloraTZP | Lilly name for the eloralintide + tirzepatide combination program [Lilly IR 2026-09-30] |
| LY3841136 | Eloralintide (mono component code) |
| LY3298176 | Tirzepatide code on the Ph2b registry title [NCT06603571] |
| LY900043 | Co-formulation code in AMPLIFY Phase 3 official titles [NCT07881432; NCT07881458] |
Practical lab tip: do not treat a vial labelled “eloralintide” plus a separate tirzepatide lot as chemically or clinically equivalent to Lilly’s future LY900043 co-formulation drug product. Combination identity is a manufacturing/regulatory construct, not a DIY mix.
Why combine amylin + GIP/GLP-1 pathways (mechanistic context)
Lilly’s EloraTZP framing: the combination was developed to simultaneously activate three complementary nutrient-stimulated hormones — GIP, GLP-1, and amylin — each acting through its own receptor to help regulate hunger and blood sugar in research descriptions, with minimal calcitonin receptor activity highlighted for the amylin component story [Lilly IR 2026-09-30]. The release cites classic neuroendocrine literature on incretins and amylin communication between gut, pancreas, and brain as background (Hayes et al., Annu Rev Nutr 2014, as footnoted in that IR).
That is pipeline rationale, not a ranking claim that EloraTZP is “better than” any approved medicine for any person, and not a license to use RUO peptides for personal weight loss.
Architecture contrast (combo vs unimolecular vs mono)
| Approach | Example | Pathways (headline) | Molecule count |
|---|---|---|---|
| Two-API combination / planned co-formulation | EloraTZP | Amylin + GIP + GLP-1 | Two peptides (eloralintide + tirzepatide) |
| Two-API combination (peer) | CagriSema | Amylin + GLP-1 | Cagrilintide + semaglutide |
| Unimolecular dual | Zenagamtide | GLP-1 + amylin in one peptide | One peptide |
| Mono-amylin | Eloralintide, petrelintide, cagrilintide mono | Amylin pathway | One peptide |
| Triple incretin (different third target) | Retatrutide | GIP + GLP-1 + glucagon | One peptide |
Cross-trial weight-loss percentages are not a ranking: populations (T2D yes/no), durations, estimands, and whether the comparator is placebo vs active tirzepatide differ.
Phase 2b study design (NCT06603571)
Every design and outcome figure below is as publicly reported. None of it is a reconstitution recipe, titration schedule for laboratory use, or eligibility advice for personal enrollment.
Registry identity
From ClinicalTrials.gov [NCT06603571]:
| Field | Public value |
|---|---|
| Official title | A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With LY3841136 and Tirzepatide, Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes |
| Status | Completed (as of fetch for this draft) |
| Phase | 2 |
| Actual enrollment | 367 |
| Start | 2024-09-20 |
| Primary completion | 2026-07-01 |
| Completion | 2026-09-14 |
| Primary outcome | Percent change from baseline in body weight (baseline → week 48) |
| Key secondary | Change in HbA1c (among others) |
| Master protocol note | Performed under master protocol W8M-MC-CWMM (NCT06143956); participation ~64 weeks in registry summary |
Population
Inclusion themes on the registry include BMI ≥27 kg/m², type 2 diabetes, HbA1c roughly 7.0–10.5%, treated with diet/exercise alone or stable metformin ± SGLT2 inhibitor for ≥3 months prior to screening (plus master-protocol weight-stability language) [NCT06603571].
How Lilly described administration in Ph2b vs future Ph3
Lilly’s 30 September 2026 release states that in NCT06603571, eloralintide and tirzepatide were administered as separate injections. The company plans to advance an EloraTZP co-formulation product into Phase 3 by the end of 2026, noting an optimized escalation schedule for those Phase 3 studies [Lilly IR 2026-09-30].
RUO note: clinical “separate injections vs co-formulation pen” research design is not a laboratory mixing protocol and does not imply that research powders can be combined to recreate clinical-trial drug product.
Randomization (Lilly “About the study”): 367 participants in the U.S. and Argentina, 1:1:1:1:1:1:1:1:1:1 to placebo, eloralintide, tirzepatide, or EloraTZP arms. Primary objective: demonstrate that eloralintide in combination with tirzepatide is superior to placebo in percent body-weight change at 48 weeks [Lilly IR 2026-09-30].
What Lilly reported at EASD 2026 (efficacy table)
Source of every number in this section: Lilly investor news release dated 30 September 2026, presenting Phase 2b results at EASD Milan [Lilly IR 2026-09-30].
Estimand footnote (sponsor): efficacy estimand represents efficacy had all randomized participants remained on study intervention (with possible dose interruptions and/or dose modifications) for 48 weeks [Lilly IR 2026-09-30].
Baselines reported: average body weight 232.4 lbs (105.4 kg); average A1C 8.1%. Primary endpoint: percent change in body weight for EloraTZP vs placebo; other comparisons secondary [Lilly IR 2026-09-30].
Phase 2b efficacy estimand results (48 weeks)
| Arm (as labeled by Lilly) | Body-weight change % | Body-weight change lbs | A1C change %-points |
|---|---|---|---|
| Elora 3 mg + TZP 5 mg | −13.2% | −30.7 | −2.2 |
| Elora 6 mg + TZP 5 mg | −19.4% | −45.1 | −2.7 |
| Elora 6 mg + TZP 10 mg | −19.9% | −46.2 | −2.6 |
| Elora 9 mg + TZP 15 mg | −23.3% | −54.1 | −2.9 |
| TZP 15 mg | −14.8% | −34.4 | −2.4 |
| Elora 3 mg | −8.2% | −19.1 | −1.1 |
| Elora 6 mg | −12.3% | −28.6 | −1.4 |
| Elora 9 mg | −11.1% | −25.8 | −1.3 |
| Placebo | −3.0% | −7.0 | −0.3 |
Sponsor narrative highlights [Lilly IR 2026-09-30]:
- Participants taking EloraTZP lost up to an average of 54.1 lbs (23.3%) vs 34.4 lbs (14.8%) with tirzepatide 15 mg.
- A1C lowered by up to an average of 2.9% with EloraTZP vs 2.4% with tirzepatide 15 mg.
- Eloralintide alone reduced body weight by up to an average of 28.6 lbs (12.3%) and A1C by up to 1.4% in this dataset.
- Lilly stated that all EloraTZP combinations met the primary and secondary endpoints as described in the release.
Label clearly: company press / congress presentation figures under the stated estimand — not a completed Phase 3 label claim and not a personal protocol. Arm labels (e.g., “Elora 9 mg + TZP 15 mg”) are trial-reported dose concepts from the sponsor table, not reconstitution or laboratory-use instructions.
Tolerability observations as reported (no advice)
From the same Lilly release [Lilly IR 2026-09-30]:
- Most common adverse events were gastrointestinal, generally mild or moderate, occurring primarily during dose escalation.
- GI events were seen more frequently in the combination arms than with eloralintide or tirzepatide alone.
- Treatment discontinuation due to adverse events: 10.8% to 27.0% with EloraTZP; 0% to 10.8% with eloralintide; 2.9% with tirzepatide; 16.7% with placebo.
These are trial-reported frequencies, not counseling instructions, not a ranking of “safer for you,” and not guidance for laboratory animal protocols. Graded AE tables by MedDRA term were not reproduced in the open press text used for this draft — do not invent them.
Phase 3 plans
Sponsor intent (EASD / IR)
Based on the Phase 2b results, Lilly said it will initiate Phase 3 trials of EloraTZP in Q4 2026, advancing a co-formulation product by the end of 2026 with an optimized escalation schedule [Lilly IR 2026-09-30]. Lilly’s Q3 2026 earnings release likewise flags Phase 2 EloraTZP results with Phase 3 trials to start in Q4 2026 [Lilly Q3 2026 IR].
Initiation / registry posting ≠ approval. No Phase 3 efficacy toplines for EloraTZP were verified for this draft.
AMPLIFY program (LY900043 co-formulation) — registry snapshot
| Field | AMPLIFY-1 NCT07881432 | AMPLIFY-2 NCT07881458 |
|---|---|---|
| Official focus | Obesity without type 2 diabetes | Obesity or overweight with type 2 diabetes |
| Status (fetch for this draft) | Not yet recruiting | Recruiting |
| Estimated enrollment | 2115 | 1000 |
| Start (registry) | 2026-12 (estimated) | 2026-10-16 (actual listed) |
| Primary completion (est.) | 2029-10 | 2029-10 |
| Primary outcome | % change in body weight, baseline → week 100 | % change in body weight, baseline → week 100 |
| Intervention theme | EloraTZP coformulation vs tirzepatide, eloralintide, placebo (multi-dose EloraTZP arms listed) | EloraTZP vs tirzepatide |
| Code in title | LY900043 | LY900043 |
Registry dates and statuses move — re-check ClinicalTrials.gov before treating any start date as fixed. Other AMPLIFY-numbered or LY900043 records may appear later; cite each NCT individually when expanding the map.
Relation to ENLIGHTEN (eloralintide monotherapy)
ENLIGHTEN is Lilly’s Phase 3 program for eloralintide alone — not the EloraTZP co-formulation.
Public example — ENLIGHTEN-1 [NCT07321886]:
| Field | Public value |
|---|---|
| Official title | Phase 3 randomized, double-blind, placebo-controlled study of once-weekly eloralintide in adults with obesity or overweight without type 2 diabetes |
| Status | Recruiting (as of fetch for this draft) |
| Estimated enrollment | 1980 |
| Start | 2026-02-06 |
| Primary outcome | Percent change in body weight, baseline → week 64 |
| Design notes | Main phase ~75 weeks; extension for participants with prediabetes |
Additional ENLIGHTEN-numbered trials appear in public registries (e.g., ENLIGHTEN-3 OSA NCT07369011). Prefer primary ClinicalTrials.gov pages when expanding; do not invent enrollment figures for unfetched records.
Why this matters for SEO / lab literacy:
- Mono-eloralintide hub remains the authority for single-agent amylin RA identity and ENLIGHTEN updates.
- This page is the combination / EloraTZP overview (Ph2b separate injections → Ph3 co-formulation LY900043 / AMPLIFY).
- Do not conflate ENLIGHTEN placebo-controlled mono results with EloraTZP vs tirzepatide combination arms.
Lilly’s EloraTZP release explicitly notes that eloralintide is already being evaluated as a single agent in Phase 3 obesity trials [Lilly IR 2026-09-30].
How EloraTZP differs from zenagamtide, CagriSema, and retatrutide
| Dimension | EloraTZP | Zenagamtide | CagriSema | Retatrutide |
|---|---|---|---|---|
| Architecture | Two peptides (planned co-formulation) | One dual peptide | Two peptides | One triple peptide |
| Headline targets | Amylin + GIP + GLP-1 | GLP-1 + amylin | Amylin + GLP-1 | GIP + GLP-1 + glucagon |
| Sponsor | Lilly | Novo Nordisk | Novo Nordisk | Lilly |
| SaiyanMed reading | This hub | What is zenagamtide | Planned CagriSema hub (not assumed live) | What is retatrutide |
Related compare pages already on site: eloralintide vs cagrilintide, eloralintide vs retatrutide.
Research / analytical identity notes
Why “EloraTZP” on a label is not identity
EloraTZP / LY900043 denotes a sponsor combination program. A research catalog listing two separate lyophilized peptides does not prove equivalence to clinical-trial co-formulation drug product. Failure modes include wrong sequences, incomplete modification, isomer content, aggregation, incorrect ratios, or simple mislabeling.
Component vs combination
| Need | Appropriate SaiyanMed path |
|---|---|
| Mono-amylin analogue education + RUO tool | What is eloralintide · Product eloralintide |
| Combination pipeline literacy | This hub only — no combo SKU claimed |
| Triple-agonist education | What is retatrutide |
| Unimolecular GLP-1/amylin education | What is zenagamtide |
Handling themes (no recipes)
Lyophilized peptides are commonly stressed by moisture, heat, light, and repeated freeze–thaw after reconstitution. Follow the batch COA and your institution’s validated procedures. This article does not provide diluent volumes, concentrations, injection instructions, titration schedules, or study protocols.
Stock status on SaiyanMed
No EloraTZP combination catalog SKU is claimed. Educational hub only. Related mono RUO tool: eloralintide. Contact research support for notify-if-stock only after explicit go-ahead and COA review — do not assume combo inventory from this article.
Myth vs evidence
| Myth | Evidence-based correction |
|---|---|
| “EloraTZP is just another name for eloralintide.” | EloraTZP is eloralintide plus tirzepatide; mono programs use ENLIGHTEN [Lilly IR 2026-09-30; NCT07321886]. |
| “Ph2b used the same co-formulation as Ph3.” | Ph2b used separate injections; Ph3 advances a co-formulation (LY900043 / AMPLIFY) [Lilly IR 2026-09-30; NCT07881432]. |
| “−23.3% is a Phase 3–confirmed label claim.” | Phase 2b, 48 weeks, efficacy estimand in obesity/overweight with T2D; not marketing authorization [Lilly IR 2026-09-30]. |
| “Same as zenagamtide / CagriSema / retatrutide.” | Different architecture and/or third pathway (see comparison table). |
| “Mix RUO eloralintide + tirzepatide powder = EloraTZP.” | Not equivalent to clinical co-formulation; out of scope for RUO supply claims. |
| “RUO vials are for personal weight loss.” | Explicitly out of scope. |
Glossary
- EloraTZP: Lilly investigational combination of eloralintide + tirzepatide.
- Eloralintide (LY3841136): Selective long-acting amylin receptor agonist (mono and combo programs).
- Tirzepatide (LY3298176): Dual GIP/GLP-1 receptor agonist.
- LY900043: Co-formulation development code on AMPLIFY Phase 3 titles.
- AMPLIFY: Phase 3 program acronym for EloraTZP co-formulation studies.
- ENLIGHTEN: Phase 3 program acronym for mono-eloralintide studies.
- Efficacy estimand (Lilly Ph2b footnote): Effect if all randomized participants remained on study intervention for 48 weeks (with possible interruptions/modifications).
- RUO: Research Use Only — not for human or veterinary administration.
- COA: Certificate of Analysis for a specific lot.
FAQ
What is EloraTZP?
EloraTZP is Eli Lilly’s investigational combination of the selective amylin receptor agonist eloralintide and the dual GIP/GLP-1 receptor agonist tirzepatide, developed to engage amylin, GIP, and GLP-1 pathways together. It is not an approved combination medicine [Lilly IR 2026-09-30].
Is EloraTZP the same as eloralintide?
No. Eloralintide is one component. EloraTZP adds tirzepatide. Mono-eloralintide Phase 3 work runs under ENLIGHTEN [NCT07321886; Lilly IR 2026-09-30].
What trial produced the EASD 2026 numbers?
Phase 2b NCT06603571: 48-week, parallel-group, double-blind, placebo-controlled weight-management study of LY3841136 and tirzepatide alone or in combination in adults with obesity/overweight and type 2 diabetes (n=367) [NCT06603571; Lilly IR 2026-09-30].
What were the headline Phase 2b results?
Under Lilly’s efficacy estimand at 48 weeks, EloraTZP arms showed body-weight change up to −23.3% (−54.1 lbs) and A1C change up to −2.9%, versus tirzepatide 15 mg −14.8% (−34.4 lbs) and −2.4% A1C (baselines ~105.4 kg and A1C 8.1%) [Lilly IR 2026-09-30].
Was Phase 2b a co-formulation?
No. Lilly states eloralintide and tirzepatide were given as separate injections in Ph2b; Phase 3 advances a co-formulation [Lilly IR 2026-09-30].
What is AMPLIFY / LY900043?
Public Phase 3 records for the eloralintide–tirzepatide co-formulation use LY900043 and the AMPLIFY acronym (e.g., AMPLIFY-1 NCT07881432; AMPLIFY-2 NCT07881458), with primary body-weight endpoints at week 100 [NCT07881432; NCT07881458].
Is EloraTZP FDA-approved?
No. Sponsor materials describe it as investigational; Phase 3 work does not equal marketing authorization [Lilly IR 2026-09-30].
How does EloraTZP differ from zenagamtide?
Zenagamtide is a unimolecular GLP-1/amylin peptide (Novo). EloraTZP is a two-drug amylin + GIP/GLP-1 combination (Lilly) [zenagamtide hub; Lilly IR 2026-09-30].
How does it differ from retatrutide?
Retatrutide is a single peptide targeting GIP, GLP-1, and glucagon. EloraTZP pairs amylin agonism with tirzepatide’s GIP/GLP-1 dual agonism as two components [retatrutide hub; Lilly IR 2026-09-30].
Does SaiyanMed sell EloraTZP?
No combo SKU is claimed on this page. For mono-amylin RUO reference material see eloralintide product. This hub is research education only.
Can I use these trial percentages as a personal protocol?
No. Trial figures are published research data under specific protocols. This page provides no dosing, reconstitution, or titration guidance.
Key takeaways
- EloraTZP = Lilly investigational eloralintide + tirzepatide combination aimed at amylin + GIP + GLP-1 pathways — not approved as this combination [Lilly IR 2026-09-30].
- Phase 2b NCT06603571 (48 wk, n=367, obesity/overweight with T2D, separate injections) reported weight change up to −23.3% and A1C change up to −2.9% under the sponsor efficacy estimand, vs tirzepatide 15 mg −14.8% / −2.4% [Lilly IR 2026-09-30].
- GI AEs were more frequent in combination arms; discontinuation due to AEs ranged 10.8–27.0% for EloraTZP in the press summary [Lilly IR 2026-09-30].
- Phase 3 co-formulation (LY900043 / AMPLIFY) is public on ClinicalTrials.gov (e.g., AMPLIFY-1/2); mono-eloralintide continues under ENLIGHTEN [NCT07881432; NCT07881458; NCT07321886].
- This page is RUO education with no SaiyanMed EloraTZP stock claim.
Related reading & research inquiry
- What Is Eloralintide?
- Eloralintide RUO product
- Eloralintide vs Cagrilintide
- Eloralintide vs Retatrutide
- What Is Retatrutide?
- What Is Zenagamtide (Amycretin)?
CTA (SKU-gated): If your laboratory needs verified mono-amylin reference material, see the eloralintide product page. We will not invent an EloraTZP combination inventory listing on this page. Notify-if-stock for any future combo-related listing requires supplier COA review and explicit go-ahead.
Research Use Only disclaimer
Research Use Only. Content summarizes published molecular, clinical-development, and analytical-quality information for laboratory professionals. It does not provide medical or veterinary advice, validated experimental protocols, dosing or reconstitution instructions, or authorization for in-vivo work. Animal research requires applicable institutional approvals. EloraTZP remains investigational as a therapeutic combination candidate. Tirzepatide-containing approved products have their own labeled indications and safety information; this article is not a substitute for those labels and is not a use guide for approved medicines or for RUO materials.
Sources & further reading
- 1. Eli Lilly — EloraTZP Phase 2b EASD results (2026-09-30) — https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide
- 2. ClinicalTrials.gov NCT06603571 — https://clinicaltrials.gov/study/NCT06603571
- 3. ClinicalTrials.gov NCT07881432 (AMPLIFY-1 / LY900043) — https://clinicaltrials.gov/study/NCT07881432
- 4. ClinicalTrials.gov NCT07881458 (AMPLIFY-2 / LY900043) — https://clinicaltrials.gov/study/NCT07881458
- 5. ClinicalTrials.gov NCT07321886 (ENLIGHTEN-1) — https://clinicaltrials.gov/study/NCT07321886
- 6. ClinicalTrials.gov NCT07369011 (ENLIGHTEN-3 OSA) — https://clinicaltrials.gov/study/NCT07369011
- 7. Eli Lilly Q3 2026 earnings — https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full
- 8. Lilly mono eloralintide Ph2 historical release — https://lilly.gcs-web.com/news-releases/news-release-details/lillys-selective-amylin-agonist-eloralintide-demonstrated
- 9. SaiyanMed — https://saiyanmed.com/what-is-eloralintide/ · https://saiyanmed.com/product/eloralintide/ · https://saiyanmed.com/eloralintide-vs-cagrilintide/ · https://saiyanmed.com/eloralintide-vs-retatrutide/ · https://saiyanmed.com/what-is-retatrutide/ · https://saiyanmed.com/what-is-zenagamtide/